source
- FDA approves Merck’s oral PCSK9 inhibitor Lipfendra, but cardiologists question its immediate impactThe FDA has granted approval to enlicitide, marketed by Merck as Lipfendra, marking the first oral PCSK9 inhibitor for lowering blood cholesterol. The drug arrives as new clinical guidelines encou…
- Vertex's $10 billion Crinetics buyout draws investor doubts over premium priceVertex was the lone bidder in a planned $10 billion acquisition of Crinetics Pharmaceuticals, a California company that focuses on endocrine medicines. Crinetics currently markets a therapy for a…